NASDAQ:CFMS - Conformis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 85.19 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.35
▼ -0.01 (-0.74%)

This chart shows the closing price for CFMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Conformis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CFMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CFMS

Analyst Price Target is $2.50
▲ +85.19% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Conformis in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 85.19% upside from the last price of $1.35.

This chart shows the closing price for CFMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Conformis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2020CowenReiterated RatingOutperform$2.00Medium
8/6/2020OppenheimerInitiated CoverageBuy$3.00High
6/24/2020CowenReiterated RatingOutperform$2.00High
5/12/2020Canaccord GenuityReiterated RatingBuy$2.00High
5/12/2020BTIG ResearchReiterated RatingHoldHigh
5/12/2020OppenheimerLower Price TargetOutperform$3.50 ➝ $3.00High
3/24/2020Canaccord GenuityReiterated RatingBuy$2.00High
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
5/2/2019OppenheimerSet Price TargetBuy$4.00High
5/2/2019BTIG ResearchReiterated RatingBuy$3.00High
4/2/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$2.50 ➝ $3.50High
12/14/2018OppenheimerSet Price TargetBuy$3.00Medium
11/2/2018CowenReiterated RatingBuy$3.00Medium
11/1/2018OppenheimerSet Price TargetBuy$3.00Medium
11/1/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$3.00 ➝ $2.50High
9/18/2018OppenheimerReiterated RatingBuyHigh
8/2/2018OppenheimerSet Price TargetBuy$4.00Low
8/2/2018BTIG ResearchReiterated RatingBuy$3.00High
7/16/2018SunTrust BanksReiterated RatingBuyHigh
5/3/2018OppenheimerSet Price TargetBuy$4.00Low
5/3/2018BTIG ResearchReiterated RatingBuy$3.00Low
4/10/2018Canaccord GenuityUpgradeHold ➝ Buy$4.00High
3/22/2018OppenheimerReiterated RatingBuyHigh
3/12/2018Canaccord GenuityReiterated RatingHoldMedium
2/21/2018CowenInitiated CoverageOutperform$1.39 ➝ $4.00High
2/8/2018Canaccord GenuityLower Price TargetHold ➝ Hold$5.00 ➝ $4.00Medium
2/8/2018OppenheimerSet Price TargetBuy$4.00Medium
1/10/2018BTIG ResearchReiterated RatingBuy$4.00Low
1/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
12/20/2017BTIG ResearchUpgradeNeutral ➝ Buy$4.00High
11/2/2017BTIG ResearchReiterated RatingHoldN/A
8/4/2017Canaccord GenuityLower Price TargetHold$8.00 ➝ $6.00Low
8/4/2017OppenheimerSet Price TargetBuy$6.00High
8/4/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Hold$6.00 ➝ $5.00High
7/16/2017BTIG ResearchReiterated RatingHoldLow
6/26/2017BTIG ResearchReiterated RatingHoldN/A
6/20/2017OppenheimerReiterated RatingBuyLow
6/20/2017BTIG ResearchInitiated CoverageNeutralLow
5/16/2017B. RileyReiterated RatingBuy$7.50Low
5/11/2017B. RileyReiterated RatingBuy$7.50High
5/11/2017Canaccord GenuitySet Price TargetHold$8.00Low
5/10/2017OppenheimerSet Price TargetBuy$9.00Low
2/21/2017B. RileyReiterated RatingBuy$7.50N/A
2/16/2017B. RileyReiterated RatingBuy$7.50N/A
2/16/2017Canaccord GenuityDowngradeBuy ➝ Hold$12.00 ➝ $7.00N/A
1/23/2017Canaccord GenuitySet Price TargetBuy$12.00N/A
11/9/2016B. RileyReiterated RatingBuy$13.00N/A
11/4/2016B. RileyReiterated RatingBuy$13.00N/A
11/4/2016JPMorgan Chase & Co.Reiterated RatingHold$11.00N/A
10/24/2016OppenheimerSet Price TargetBuy$13.00N/A
9/21/2016B. RileyInitiated CoverageBuy$13.00N/A
9/19/2016SunTrust BanksInitiated CoverageBuy$14.00N/A
9/15/2016B. RileyInitiated CoverageBuy$13.00N/A
8/9/2016JPMorgan Chase & Co.Lower Price TargetNeutral$11.00 ➝ $8.00N/A
8/9/2016OppenheimerBoost Price TargetOutperform$12.00 ➝ $13.00N/A
(Data available from 7/24/2016 forward)
Conformis logo
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Read More

Today's Range

Now: $1.35
Low: $1.29
High: $1.51

50 Day Range

MA: $1.04
Low: $0.82
High: $1.36

52 Week Range

Now: $1.35
Low: $0.60
High: $1.51

Volume

9,940,656 shs

Average Volume

2,551,055 shs

Market Capitalization

$246.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Conformis?

The following Wall Street sell-side analysts have issued research reports on Conformis in the last year: Cowen Inc, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for CFMS.

What is the current price target for Conformis?

2 Wall Street analysts have set twelve-month price targets for Conformis in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 85.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting CFMS will reach $3.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $2.00 for Conformis in the next year.
View the latest price targets for CFMS.

What is the current consensus analyst rating for Conformis?

Conformis currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CFMS will outperform the market and that investors should add to their positions of Conformis.
View the latest ratings for CFMS.

What other companies compete with Conformis?

How do I contact Conformis' investor relations team?

Conformis' physical mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier's listed phone number is 781-345-9001 and its investor relations email address is [email protected] The official website for Conformis is www.conformis.com.